Lung Cancer
-
From the Editor-in-Chief
Something in the Air: Pollution and CancerAir pollution, both indoors and outdoors, is a leading cause of lung cancer, especially among nonsmokers.
by William G. Nelson, MD, PhD
-
-
Forward Look
Ushering in a New Standard of CareTargeted therapy extends progression-free survival in people with stage III EGFR-mutated lung cancer.
by Darcy Lewis
-
Making Their MarkWith targeted therapy options available for a growing number of cancer types, biomarker testing is making a difference for more people with solid cancers.
by Kendall K. Morgan
-
Telehealth Palliative Care Provides the Same Benefits as In-person CareResearchers hope effective telehealth will increase access to palliative care for more cancer patients.
by Taneia Surles
-
Immunotherapy Drug Tarlatamab Approved for Advanced Small Cell Lung CancerThe drug showed promise in treating small cell lung cancer that had progressed during or after chemotherapy.
by Laura Gesualdi-Gilmore
-
Extending Remissions in Lung CancerImmune checkpoint inhibitors are effective against non-small cell lung cancer in some patients. Researchers are investigating who benefits from the drugs and when they should be administered for maximum impact.
by Natalie Slivinski
-
Forward Look
Immunotherapy for Early-stage Lung CancerImmune checkpoint inhibitors can reduce the risk of recurrence for early-stage non-small cell lung cancer, but researchers are still exploring optimal timing for patients who have surgery.
by Anna Napolitano
-
Overcoming Lung Cancer Stigma With UnderstandingShirley Muñoz wants to use her experience as a younger lung cancer patient to break down barriers to care for her community through translation and advocacy.
by Cameron Walker
-
Forward Look
The Lasting Benefit of Immune Checkpoint InhibitorsStudy suggests people with advanced lung cancer who have a sustained response to immunotherapy can safely stop treatment after two years.
by Lindsay Modglin
